Abstracts Archive - Page 104 of 2607 - ACR Meeting Abstracts

Abstract Number: 1084 • ACR Convergence 2025
Access to rheumatology care in patients with new diagnosis of polymyalgia rheumatica: analysis from a national inception cohort
Sebastian E Sattui¹, Orysya Soroka², Manuel Carpio Tumba³, Emily Holladay⁴, Fenglong Xie⁵, Sarah Mackie⁶, Jeffrey Curtis⁷, Robyn Domsic³ and Iris Navarro-Millan⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Weill Cornell Medicine, New York, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Leeds, Leeds, United Kingdom, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY
Background/Purpose: Patients with polymyalgia rheumatica (PMR) are commonly diagnosed and cared for by non-rheumatology providers (i.e., primary care). Lack of access to specialty care can…
Abstract Number: 1121 • ACR Convergence 2025
Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
Tao Ming Sim¹, May Shuen Tang¹, Qai Ven Yap², Alvin Wong¹, Yiqing Huang¹ and Frank Sen Hee Tay¹, ¹National University Hospital, Singapore, Singapore, ²National University of Singapore, Singapore
Background/Purpose: Use of immune checkpoint inhibitors (ICIs) can lead to a broad spectrum of immune-related adverse events (irAEs) affecting multiple organ systems. No clear pattern…
Abstract Number: 1005 • ACR Convergence 2025
CD49a Contributes to Binding and Survival of Synovial Resident Memory T cells
Yusuke Miyashita¹, Yang Yang², Madison Mangin³, Maryrose Hahn² and Margaret Chang², ¹Boston Children's Hospital, Brookline, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, St Simons Island, GA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease featured with recurrent inflammation in the same joints, a characteristic termed joint-specific memory. We previously demonstrated…
Abstract Number: 1079 • ACR Convergence 2025
Sociodemographic, Clinical, and Community-Level Deprivation Factors are Associated with Health-Related Quality of Life in Systemic Sclerosis
Sarah Smith¹, Paula Ramos², Dulaney Wilson³, Diane Kamen⁴ and Richard Silver¹, ¹Medical University of South Carolina, Charleston, SC, ²Emory University School of Medicine, Atlanta, GA, ³Medical University of South Carolina, Charleston, ⁴Medical University of South Carolina, Johns Island, SC
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease with heterogeneous manifestations and significant impairment in health-related quality of life (HRQoL). SSc outcomes are shaped…
Abstract Number: 1106 • ACR Convergence 2025
Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Ko-Jen Li¹, Ting-Wei Chang², Tso-Ting Lai³, Jui-Hung Kao⁴, TING-YUAN LAN⁵, Tai-Ju Lee⁶, pei-Hsinq lai⁷, Shao-Yu Pai⁸, Chiehyu Shen⁹ and Song-Chou Hsieh¹⁰, ¹National Taiwan University Hospital, Taipei, Taiwan, ²National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, ³Naitional Taiwan University Hospital, Taipei, Taiwan (Republic of China), ⁴Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁵National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ⁶National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁷Taipei City Hospital, Taichung, Taiwan, ⁸National Taiwan University Hospital, Taichung City, Taiwan (Republic of China), ⁹National Taiwan University Hospital, Taipei city, Taiwan, ¹⁰National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: Hydroxychloroquine (HCQ) retinopathy is a progressive, vision-threatening retinal disease. While HCQ is typically discontinued after toxicity is detected, some patients undergo tapering due to…
Abstract Number: 1105 • ACR Convergence 2025
Association between pre-existing rheumatoid arthritis and immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors
Kevin Sheng-Kai Ma¹, You Wu², Rachael Stovall², Jean Liew³ and Namrata Singh⁴, ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²University of Washington, Seattle, WA, ³Boston University, Boston, MA, ⁴University of Washington, Bellevue, WA
Background/Purpose: Immune checkpoint inhibitors (ICIs), widely used to treat a variety of cancers, are associated with immune-related adverse events (irAEs) that are increasingly encountered in…
Abstract Number: 1130 • ACR Convergence 2025
Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
Kiara Tan¹, Jiaqi Wang¹, Saiajay Chigurupati², Gregory Challener³, Natalie McCormick¹, Sharan Rai⁴, Florence Porterfield⁵, Chika Anekwe¹, Dong Wook Kim⁶, Fatima Stanford⁷, Caroline Apovian⁸, Hyon K. Choi⁹ and Chio Yokose¹⁰, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Division of Endocrinology, Massachusetts General Hospital, Boston, ⁶Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, ⁷Neuroendocrine Unit, Pediatric Endocrinology, Massachusetts General Hospital, Boston, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ¹⁰Massachusetts General Hospital, Waltham, MA
Background/Purpose: Obesity affects >50% of individuals with gout and is the most important modifiable risk factor for gout. Thus, novel anti-obesity medications (AOM, e.g., semaglutide…
Abstract Number: 1052 • ACR Convergence 2025
“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use
Isabella Hartel¹, Jay Patel¹, Justin Levinson¹, Sancia Ferguson², Carmen Campbell¹, Amannda Weber³, Shelby Gomez⁴, David Gazeley⁵, Ali Duarte-Garcia⁶, Jennifer Barton⁷ and Shivani Garg⁸, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, ³University of Wisconsin (UW), UW Health, Madison, WI, ⁴University of Wisconsin, School of Pharmacy, Madison, WI, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Mayo Clinic, Rochester, MN, ⁷VA Portland Health Care System/OHSU, Portland, OR, ⁸University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Guidelines recommend limiting chronic prednisone use ( >5 mg/d for >3-6 mos.) given higher risks of fractures, infections, and damage. Yet, patients struggle to…
Abstract Number: 1071 • ACR Convergence 2025
Depression and Mental Health Service Gaps in Autoimmune Disease: Insights from a Simulated BRFSS Dataset
Malay Rathod¹, Shivani Modi², Veera Durga Vaishnavi Kurra³, Karan Yagnik⁴ and Doantrnag Du⁴, ¹Monmouth Medical Center, Ewing, NJ, ²Jefferson Einstein Montgomery Hospital, Ewign, NJ, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Monmouth Medical Center, Long Branch, NJ
Background/Purpose: Autoimmune diseases are complex conditions that may predispose individuals to an increased mental health burden, including depression. The immune system leads to inflammation in…
Abstract Number: 1081 • ACR Convergence 2025
Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment
Ramsha Riaz¹, Lifang Zhang², Andrea Berger², Hema Srinivasan², Lisa Schroeder³ and Jonida Cote⁴, ¹Geisinger Medical Center, Danville, PA, ²Geisinger Health System, Danville, PA, ³Geisinger, Danville, PA, ⁴Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: Recognizing health care disparities in Rheumatoid Arthritis is crucial to improving outcomes. This study analyzes factors contributing to RA care inequities.Methods: We examined RA…
Abstract Number: 1100 • ACR Convergence 2025
Associations Between Pre-Existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
Gregory Challener¹, Chen Wang², David Gritsch², Ilana Usiskin³, Zandra E. Walton¹, Minna Kohler⁴, Hyon K. Choi⁵ and Jeffrey Sparks⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Harvard T.H. Chan School of Public Health, Boston, ³Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Chimeric antigen receptor (CAR) T cell therapy is being investigated to treat individuals with autoimmune diseases. Data regarding the safety of CAR T cell…
Abstract Number: 1114 • ACR Convergence 2025
Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
Mei-Feng Shi¹, Fang-Shu Zou¹, Xiao-Na Ma¹, Wei Feng¹, Yi-Fang Zhang², Chang-Song Lin¹, Min-Ying Liu² and Qiang Xu¹, ¹Guangzhou University of Traditional Chinese Medicine, Guangzhou, China (People's Republic), ²The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China (People's Republic)
Background/Purpose: Methotrexate (MTX) is a first-line treatment for autoimmune diseases, including rheumatoid arthritis (RA). Its potential risk of inducing type 2 diabetes mellitus (T2DM) remains…
Abstract Number: 1136 • ACR Convergence 2025
The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts
Bayram Farisogullari¹, Pedro Machado², Stephanie Finzel³, Graeme Carroll⁴, Geraldine mcCarthy⁵, John Stack⁶, Simone Parisi⁷, Graca Porto⁸, richette pascal⁹, Gyorgy Nagy¹⁰, Marton Weidl¹⁰, Ann Rosenthal¹¹, Pascal Guggenbuhl¹², Katarzyna Banaszkiewicz¹³, Barbara Butzeck¹⁴, Howard Don¹⁵, Svenja Engelhardt¹⁶, Jeremy Shearman¹⁷, David Mitchell¹⁸, Jane Barker¹⁹, Valerie Brueton¹⁹, Philip Coathup¹⁹, Jacquie Dowsett¹⁹, Marie Duncan¹⁹, Tracey Dunleavy¹⁹, Ian Fish¹⁹, Allin Hoggarth¹⁹, Mark McKinnon¹⁹, James Minter¹⁹, Tim Osborne¹⁹, Marguerite Smith¹⁹, Christine Wright¹⁹ and Patrick Kiely²⁰, ¹University College London, London, ²Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁴Fiona Stanley Hospital, Perth, Western Australia, Australia, ⁵Mater Misericordiae University Hospital, Dublin, Ireland, ⁶Mater Misericordiae University Hospital, Dublin, Dublin, Ireland, ⁷Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁸Centro Hospitalar Universitário de Santo António, Unidade Local de Saúde de Santo António, Porto, Portugal, ⁹Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, ¹⁰Buda Hospital of the Hospitaller Order of Saint John of God, Budapest, Hungary, ¹¹Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Wisconsin, ¹²Rennes University Hospital, Rennes, France, ¹³University Clinical Center in Gdańsk, Smoluchowskiego ¹⁷ Street, ⁸⁰-⁹⁵² Gdańsk, Poland., Gdańsk, Poland, ¹⁴European Federation of Associations of Patients with Haemochromatosis,, Croissy-sur-Seine, France, ¹⁵Haemochromatosis International, Barnstaple, United Kingdom, ¹⁶University of Freiburg, Freiburg im Breisgau, Germany, ¹⁷South Warwickshire University Foundation Trust and Warwick Medical School,, Warwick, United Kingdom, ¹⁸Clongriffin Medical Centre, Dublin, Ireland, ¹⁹c/o St George's University Hospitals NHS Trust, London, United Kingdom, ²⁰St George's University Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: A EULAR task force developed classification criteria (CC) for Haemochromatosis Arthropathy (HA) using a cohort of people with the C282Y homozygous mutation and arthropathy…
Abstract Number: 1067 • ACR Convergence 2025
Investigating Barriers to Care through Childhood Opportunity, Social Vulnerability, Area Deprivation, and Distance to Care in Pediatric Localized Scleroderma
Karen Lin¹, Yuhan Ma¹, Simrat Morris² and Kristina Ciaglia³, ¹Scottish Rite for Children, Dallas, TX, ²UT Southwestern Medical Center and Scottish Rite for Children, Dallas, TX, ³UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX
Background/Purpose: Delays in diagnosis and treatment of pediatric localized scleroderma (LS) are common due to the under-recognition at initial presentation. While previous studies on pediatric…
Abstract Number: 1015 • ACR Convergence 2025
Refining Administrative Algorithms For Accurate Identification of Patients with Systemic Sclerosis In Trinetx Research Network
Gulsen Ozen¹, Michael O'Rorke², Paul Romitti² and Robyn Domsic³, ¹University of Iowa, Carver College of Medicine, Division of Immunology, Coralville, IA, ²University of Iowa College of Public Health, Department of Epidemiology, Iowa City, IA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Large data-driven medical research is invaluable in answering questions about epidemiology, genetics, therapeutics, and outcomes of rare diseases. Systemic sclerosis (SSc) is rare yet…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].